Research News for February 12, 2020
advertisement
- New research looks at type 1 diabetes and changes in the environment
- Longitudinal Metabolome-Wide Signals Prior to the Appearance of a First Islet Autoantibody in Children Participating in the TEDDY Study. (HTML)
- Exposure to Closed Loop Barriers Using Virtual Reality. (HTML)
- An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. (HTML)
- Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes. (HTML)
- The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. (HTML)
- A Novel Quantitative Approach to Staging and Assessing Recovery from Type 1 Diabetes Mellitus: The Type 1 Diabetes Mellitus Metabolic Recovery Index. (HTML)
- New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine
- MODY Testing in Patients Newly Diagnosed with Type 1 Diabetes
- Possible Associations of Disturbed Neurometals and Ammonia with Glycaemic Control in Type 1 Diabetic Children with Attention Deficit Hyperactivity Disorder. (HTML)
- Influence of cardiac autonomic neuropathy on cardiac repolarisation during incremental adrenaline infusion in type 1 diabetes. (HTML)
- CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes. (HTML)
- Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus®): a randomized open-label clinical trial. (HTML)
- A novel and easy method to locate and remove first approved long-term implantable glucose sensors. (HTML)
- Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes. (HTML)
